Comparative effectiveness and safety of upadacitinib versus vedolizumab in anti-TNF-exposed patients with ulcerative colitis

医学 维多利祖马布 溃疡性结肠炎 内科学 中止 优势比 倾向得分匹配 入射(几何) 胃肠病学 不利影响 回顾性队列研究 外科 队列 治疗药物监测 队列研究 炎症性肠病 前瞻性队列研究 药物治疗 抗菌剂 意向治疗分析
作者
Jian Wan,Hao Zhang,Xiaojie Yuan,Zhengyu Ren,Sumei Sha,Changyue Wu,Yingchao Li,Xin Liu,Xin Wang,Jiaming Zhou,Chuhan Hu,Fei Chen,Min Chen,Jie Liang,Kaichun Wu
出处
期刊:Inflammatory Bowel Diseases [Oxford University Press]
标识
DOI:10.1093/ibd/izag179
摘要

BACKGROUND & AIMS: Head-to-head comparative evidence between upadacitinib and vedolizumab for anti-tumor necrosis factor (TNF)-exposed ulcerative colitis (UC) patients is lacking. This study compared their real-world effectiveness and safety. METHODS: This multicenter retrospective cohort included anti-TNF-exposed UC patients with a partial adapted Mayo score ≥ 2 who received upadacitinib or vedolizumab between March 2021 and February 2026 and had a minimum of 16 weeks of follow-up. Clinical outcomes were assessed at weeks 16 and 26, with endoscopic evaluation at week 26. The primary outcome was steroid-free symptomatic remission (SFSR) at week 16, defined as rectal bleeding subscore = 0 and stool frequency subscore ≤ 1, with no corticosteroid use for at least 2 weeks prior to assessment. Propensity score-based inverse probability of treatment weighting (IPTW) was used to adjust for imbalance of baseline characteristics. RESULTS: A total of 242 patients were analyzed (120 vedolizumab, 122 upadacitinib). After IPTW, upadacitinib was superior in achieving week-16 SFSR (71.7% vs 54.6%; adjusted odds ratio [aOR] 2.11, 95% CI, 1.67-2.65, P < .001). At week 26, upadacitinib remained superior in SFSR (82.6% vs 61.8%; aOR 2.93, 95% CI, 1.85-4.66, P < .001) and also demonstrated higher rates of endoscopic improvement (75.3% vs 47.1%; aOR 3.42, 95% CI, 2.57-4.56, P < .001), and endoscopic remission (41.5% vs 22.2%; aOR 2.49, 95% CI, 1.71-3.63, P < .001). There was no significant difference regarding the risk of drug discontinuation between the two groups (aHR 0.46, 95% CI, 0.20-1.04, P = .058). However, the overall incidence of adverse events was higher with upadacitinib (0.475 vs 0.213 per person-year, P < .001), while the rates of serious adverse events were not significantly different between groups. CONCLUSIONS: Upadacitinib demonstrates superior effectiveness over vedolizumab in anti-TNF-exposed UC but carries a higher burden of adverse events, highlighting the need for personalized benefit-risk assessment to guide treatment selection.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zb完成签到,获得积分10
刚刚
Ava的应助被甜甜十三采纳,获得10
刚刚
1秒前
null的应助被馥郁采纳,获得10
2秒前
爆米花的应助被洛枝采纳,获得10
2秒前
绿叶发布了新的文献求助10
2秒前
yzy发布了新的文献求助10
3秒前
NIIER完成签到,获得积分10
3秒前
MQL完成签到,获得积分10
3秒前
3秒前
4秒前
4秒前
丘比特的应助被弘毅采纳,获得10
4秒前
熄灯完成签到,获得积分10
5秒前
6秒前
7秒前
8秒前
cc1完成签到,获得积分10
8秒前
Yexin发布了新的文献求助10
9秒前
null的应助被熄灯采纳,获得10
10秒前
10秒前
甜甜十三完成签到,获得积分10
10秒前
lkl完成签到,获得积分10
10秒前
无极微光的应助被隔阂鬼采纳,获得20
10秒前
11秒前
Fl完成签到,获得积分20
11秒前
比天堂更美丽完成签到,获得积分10
11秒前
12秒前
12秒前
yzy完成签到,获得积分10
13秒前
paek完成签到,获得积分10
13秒前
orixero的应助被东山采纳,获得10
14秒前
14秒前
Mujuas发布了新的文献求助10
14秒前
23333完成签到,获得积分10
15秒前
核壳结构发布了新的文献求助10
15秒前
15秒前
丘比特的应助被黄123huang_采纳,获得10
16秒前
我勒个大豆这么好用完成签到,获得积分10
16秒前
卡诺斯明发布了新的文献求助10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153573
求助须知:如何正确求助?哪些是违规求助? 9550279
关于积分的说明 21697424
捐赠科研通 7742161
什么是DOI,文献DOI怎么找? 3425546
关于科研通互助平台的介绍 2550636
邀请新用户注册赠送积分活动 2469181